T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus

Clinical Immunology

Volumn 132, Issue 3, 2009, Pages 362-370

  Zhou, Ying ^a   Yuan, Jun ^a   Pan, Yujun ^b   Fei, Yiping ^b,c   Qiu, Xiangning ^a   Hu, Nan ^a   Luo, Yongqi ^a   Lei, Wenzhi ^a   Li, Yaping ^a   Long, Hai ^a   Sawalha, Amr H ^b,c,d   Richardson, Bruce ^e,f   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

CD40 ligand; ; DNA methylation; ; Immunoglobulin G; ; Systemic lupus erythematosus

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AZACITIDINE; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; HYDRALAZINE; IMMUNOGLOBULIN G; MESSENGER RNA; PROCAINAMIDE;

ADULT; ARTICLE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; COCULTURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; MALE; MONOTHERAPY; PLASMA CELL; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; X CHROMOSOME INACTIVATION;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MALE; SEX CHARACTERISTICS; T-LYMPHOCYTES; TRANSFECTION; YOUNG ADULT;

EID: 67651152585     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.05.011     Document Type: Article

References (33)

1. Sawalha A.H., and Harley J.B. Antinuclear autoantibodies in systemic lupus erythematosus. Curr. Opin. Rheumatol. 16 (2004) 534-540
2. Soto M.E., Vallejo M., Guillén F., Simón J.A., Arena E., and Reyes P.A. Gender impact in systemic lupus erythematosus. Clin. Exp. Rheumatol. 22 (2004) 713-721
3. Lockshin M.D. Sex ratio and rheumatic disease: excerpts from an Institute of Medicine report. Lupus 11 (2002) 662-666
4. Vogel L.A., and Noelle R.J. CD40 and its crucial role as a member of the TNFR family. Semin. Immunol. 10 (1998) 435-442
5. Lu L.F., Cook W.J., Lin L.L., and Noelle R.J. CD40 signaling through a newly identified tumor necrosis factor receptor-associated factor 2 (TRAF2) binding site. J. Biol. Chem. 278 (2003) 45414-45418
6. Miga A., Masters S., Gonzalez M., and Noelle R.J. The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunol. Invest. 29 (2000) 111-114
7. Ciferská H., Horák P., Hermanová Z., Ordeltová M., Zadrazil J., Tichý T., and Scudla V. The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin. Rheumatol. 26 (2007) 723-728
8. Goules A., Tzioufas A.G., Manousakis M.N., Kirou K.A., Crow M.K., and Routsias J.G. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 26 (2006) 165-171
9. Mohan C., Shi Y., Laman J.D., and Datta S.K. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154 (1995) 1470-1480
10. Weber M., and Schübeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr. Opin. Cell Biol. 19 (2007) 273-280
11. Cornachia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140 (1988) 2197-2200
12. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., and Richardson B. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum. 48 (2003) 746-756
13. Oelke K., and Richardson B. Decreased T cell ERK pathway signaling may contribute to the development of lupus through effects on DNA methylation and gene expression. Int. Rev. Immunol. 23 (2004) 315-331
14. Lu Q., Wu A., Tesmer L., Ray D., Yousif N., and Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J. Immunol. 179 (2007) 6352-6358
15. Brunner H.I., Feldman B.M., Bombardier C., and Silverman E.D. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 42 (1999) 1354-1360
16. Lu Q., Kaplan M., Ray D., Ray D., Zacharek S., Gutsch D., and Richardson B. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum. 46 (2002) 1282-1291
17. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., and Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33 (1990) 1665-1673
18. Cron R.Q. CD154 transcriptional regulation in primary human CD4 T cells. Immunol. Res. 27 (2003) 185-202
19. Datta S.K., Kaliyaperumal A., Mohan C., and Desai-Mehta A. T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Lupus 6 (1997) 333-336
20. Zhou Y., and Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun. Rev. 7 (2008) 376-383
21. Balada E., Ordi-Ros J., and Vilardell-Tarres M. DNA methylation and systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1108 (2007) 127-136
22. Richardson B.C., Strahler J.R., Pivirotto T.S., Quddus J., Bayliss G.E., Gross L.A., O Rourke K.S., Powers D., Hanash S.M., and Johnson M.A. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 35 (1992) 647-662
23. Oelke K., Lu Q., Richardson D., Wu A., Deng C., Hanash S., and Richardson B. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum. 50 (2004) 1850-1860
24. Kaplan M.J., Lu Q., Wu A., Attwood J., and Richardson B. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J. Immunol. 172 (2004) 3652-3661
25. Arai J., Yasukawa M., Takada K., Tange Y., Saiki O., Horiuchi T., Tamai T., and Fujita S. Non-X-linked hyper-IgM syndrome with systemic lupus erythematosus. Clin. Exp. Rheumatol. 16 (1998) 84-86
26. Heard E., and Disteche C.M. Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev. 20 (2006) 1848-1867
27. Park Y., and Kuroda M.I. Epigenetic aspects of X-chromosome dosage compensation. Science 293 (2001) 1083-1085
28. Hellman A., and Chess A. Gene body-specific methylation on the active X chromosome. Science 315 (2007) 1141-1143
29. Chang S.C., Tucker T., Thorogood N.P., and Brown C.J. Mechanisms of X-chromosome inactivation. Front. Biosci. 11 (2006) 852-866
30. Vakkalanka R.K., Woo C., Kirou K.A., Koshy M., Berger D., and Crow M.K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum. 42 (1999) 871-881
31. Yazdany J., and Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 13 (2004) 377-380
32. Davidson A., Wang X., Mihara M., Ramanujam M., Huang W., Schiffer L., and Sinha J. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann. N. Y. Acad. Sci. 987 (2003) 188-198
33. Anolik J.H., and Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. 19 (2005) 859-878